Neurocycle Therapeutic's Pipeline

pipeline 04 nov 

NCT-10004
NCT-10004 is our canine and human clinical candidate for pruritus associated with atopic and allergic dermatitis.

Learn more

NCT-10001
Our lead candidate has demonstrated efficacy in animal models of pain, anxiety, and epilepsy at doses that do not cause side effects.

Learn more

NCT-10003
Our lead neurosteroid is expected to have decreased CNS side effects and an improved dosing profile relative to competitor neurosteroids.

Learn more